A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia
Latest Information Update: 10 May 2022
At a glance
- Drugs Niacin/laropiprant (Primary) ; Laropiprant; Niacin
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme
- 06 Dec 2011 New trial record